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Introduction 
 The last few years have seen an explosion of activity in the identification of common, low-penetrance 
susceptibility alleles for a range of complex diseases and other traits using genome-wide 
association studies (GWAS)1. As of June 2010 there have been 904 published genome-wide 
associations (at p<5x10-8) for 165 traits2.  Of these, 193 loci were associated with modified 
risk of 11 different cancer types2. Despite the success in identifying risk associated loci, a 
causal SNP or the molecular basis of risk etiology has been determined in only a small 
fraction of these documented associations3-5.   
 A recent Nature Genetics editorial on post-GWAS analyses began to put this problem 
in sharper focus and suggested that there should be a more significant investment in 
functional characterization of identified risk loci6. Importantly, the development of reliable 
biomarkers and effective preventive and therapeutic agents made possible by these 
discoveries is predicated on a detailed understanding of biological function. The editorial 
made a distinction between two types of functional analysis. The first comprises a 
preliminary investigation that includes resequencing, association analysis of all variants 
within the region of linkage disequilibrium (LD), investigation of risk-associated SNPs as 
modifiers of monogenic traits, genomic analysis of gene expression in human tissues, screens 
for somatic mutations on risk haplotypes, and epigenetic analysis of human tissues in the 
regions of the GWAS SNPs. Similar guidelines have been proposed elsewhere, in the context 
of loci that underlie complex traits7.  
 However, there is second stage of functional analysis geared towards understanding 
the biological mechanism of risk enhancement and causality. Whereas in-depth analysis 


































identification of general hypotheses that can be tested in a systematic way will accelerate 
analysis. Thus, in this paper we propose principles for the initial functional characterization 
of cancer risk loci to bridge this information gap.   
 Several challenges lie ahead in assigning functionality to susceptibility SNPs. For 
example, most effect sizes are small relative to effects seen in monogenic diseases, with per 
allele odds ratios usually ranging from 1.15 to 1.3, despite an occasional outlier such as 
KITLG in testicular germ cell cancer (OR=3.08)8,9. Thus, the functional effects of SNPs are 
likely to be subtle. It is unclear whether current molecular biology methods have enough 
resolution to differentiate such small effects. In addition, we anticipate that it will be difficult 
to address function for biological effects that are non-cell autonomous, are specific to certain 
developmental stages, or act at a site distant from the tissue-of-origin of the cancer. The study 
of such effects might benefit from in vivo models. An ultimate goal for any disease is to link 
genetic variation to causation.  This is currently beyond the capability of complex disease 
research. Our objective here is therefore to provide a set of recommendations to optimize the 
allocation of effort and resources in order maximize the chances of elucidating the functional 
contribution of specific loci to the disease phenotype. It has been estimated that 88% of 
currently identified disease-associated SNP are intronic or intergenic 4.Thus, in this paper we 
will focus our attention on the analysis of non-coding variants and outline a hierarchical 
approach for post-GWAS functional studies.  Connecting a risk allele to a target gene(s) is 
particularly tractable intermediate point in this work.  The unifying hypotheses that are 
applicable across these studies are: 
1. That there is a transcript (coding or non-coding) that is has not yet been annotated and 
associates with a risk locus. 
2. That the risk locus is a regulatory element affecting the expression of one or more 
annotated transcribed regions of the genome. 
 
 Defining regional boundaries and the assembly of layered genomic data 
The general approach underlying current GWAS is to identify disease association through 
surrogate SNP markers that capture linkage disequilibrium (LD) relationships across the 
genome.  This approach means that any GWAS data generated using commercial SNP arrays 
are limited by the depth of genomic coverage and representation of LD structure on those 
arrays. Unfortunately, recent data suggest that only 60% or less of the common SNP 
information (>5%) and less than 50% of variants with a frequency of >2.5% are found on 
SNP arrays used in the majority of GWAS conducted to date when compared to the 1000 
Genomes Project1. While a new generation of SNP arrays have been developed and address 
this issue of genome coverage (at least for European populations), the degree (or lack thereof) 
of common SNP content in GWAS studies has important implications not only for missing 
“dark matter” signals but also for subsequent post GWAS functional characterization studies 
of known associations.  In the vast majority of cases, any association identified through 
GWAS would be predicted to be between a surrogate maker (e.g., tagSNP) and the disease 
trait rather than a surrogate marker and a causal variant, as SNP arrays were designed using 
surrogates chosen to capture LD structure on SNP arrays rather than for any functional 
reasons. Therefore evaluation of all common SNPs across associated regions will be desirable 
to fully characterize the biologic implications of disease associations.  Unfortunately, current 
HapMap information is incomplete with respect to identifying all common variant 
information and may not capture the genetic diversity of the populations being used in 


































data and will capture the majority of common variants, it remains to be determined whether it 
will provide complete common (>5%) SNP coverage across the entire genome, including 
intergenic regions and gene deserts where the majority of associations have been mapped.  
Looking ahead it is also important to note that currently the 1000 Genomes Project will not 
capture adequate information on rare variants (<1%) and there is a growing interest in the 
role of multiple rare variants in disease risk, which will require targeted or whole genome 
sequencing of 1,000s - 10,000s of samples.  
Understanding LD structure in the region across a risk locus will be critical to delimit the size 
of the target region and define the costs of the undertaking. It is still unclear which r2 
threshold should be set in defining LD structure as the causal SNP potentially could be in LD 
with the associated SNP at an r2 of 0.2 or even less.  Ideally, the LD structure should be 
defined using genotyping results from the GWAS population in whom original association 
was identified.  For studies involving populations not studied in the HapMap or pilot 1000 
Genomes Project, variant discovery or additional genotyping is likely to have to be 
undertaken prior to defining LD relationships due to the fact that it is not known how well the 
available SNP arrays capture the genomic diversity outside of these HapMap populations. 
Alternatively LD structure does not necessarily need to be considered and boundaries of 
sequencing could be defined by arbitrary size (such as 1Mb across the associated SNP region) 
or by taking the most distal and proximal SNPs with r2>0.1. Although somewhat arbitrary 
these approaches represent a workable start point in the absence of data precisely defining LD 
structure as a start point.  
If planning to make use of next generation sequencing data to define regional boundaries, a 
second consideration is depth of sequencing coverage.  For example, the pilot phase of the 
1000 Genomes Project has completed low-coverage (4x) whole genome sequencing on 180 
individuals (60 from the each of three populations: African, Asian, and Northern European) 
and deep-coverage (>30x) whole genome sequencing on 2 trios (African and Northern 
European; also re-sequenced at low-coverage). In addition, deep-coverage (>30x) exome re-
sequencing data will soon be available on hundreds of samples and eventually 1000. 
Remarkably, even at low-coverage it is expected that the majority of common variants, intra- 
as well as inter-genic, with a minor allele frequency (MAF) >5%, will be identified. 
Complete coverage is expected for those common variants, intra- and inter-genic once again, 
with MAF >10%. These data offer a substantially improved value proposition to genetic 
variation discovery when compared to genome-wide arrays while at the same time pushing 
deeper into the minor allele frequency spectrum. That said, considerably deeper coverage will 
be needed and in more populations if rare variants are to be identified let alone novel 
hypotheses tested. Pooling of subjects for sequencing can be used to reduce costs but could 
limit coverage for individual samples in the pool and another genotyping step may need to be 
introduced to obtain individual level data.  Additional biological data could also be used to 
define the region for analysis.  For example, boundaries could be reduced due to a compelling 
candidate gene/transcript mapping to the region. However if any of these a priori hypotheses 
based on known biological data are used to reduce the extent of sequencing it should be 
recognized that this decision is generally made for cost reduction purposes only. Relying on 
biological assumptions undermines the agnostic approach one of the main advantages of 
GWAS. Finally, the majority of published GWAS data comes from European populations, 
but incorporating GWAS information from other ethnic groups such as African-Americans 
could potentially reduce the target region if a similar association was found in this population 
as the African-American population generally has smaller LD block structure than the 
European population, as exemplified by a recent study on cocaine dependence10. Therefore, 


































to be sequenced, incorporating information such as LD structure, and the overall sequencing 
cost. 
   
Genetics of Gene Expression 
Having defined the target region, and identified all common (>1-5% depending on depth of 
sequencing) variants within a risk locus by resequencing and in silico, a next step in 
progressing to functional characterisation is to explore associations between statistically 
significant SNPs and the expression of genes. Such associations offer a thread from which to 
build functional validation, although they do not necessarily mean that the genes cause the 
clinical trait. Gene expression is a heritable trait.  Transcript abundance varies in the human 
population (similar to height and blood pressure) and thus can be considered a trait that is 
amenable to genetic mapping.  A number of landmark studies have unequivocally 
demonstrated that a substantial fraction of transcripts in the human genome are influenced by 
inherited variation 11-15.  Genetic variants affecting transcript levels are often referred to as 
expression quantitative trait loci (eQTLs).  eQTLs can be located near the gene they regulate 
or far away.  The distinction between local and distant is often arbitrary; however, for most 
studies local has usually been defined as being within 1 megabase of the variant under 
consideration.  Distant can involve interactions between an eQTL and a gene located in 
different non-homologous chromosomes. As has been previously pointed out, we prefer the 
terminology of local and distant rather than cis- and trans- which connotes mechanism 16.  
Certain principles have emerged from these studies: i) eQTLs tend to explain a greater 
proportion of trait variance than is typically seen for risk alleles and clinical traits; this 
observation translates into eQTLs and gene expression traits that can be discovered with 
smaller sample sizes than association studies between inherited variation and clinical traits 
(such as disease risk), ii) local eQTLs tend to have larger effects on gene expression than 
distant eQTLs and are therefore easier to discover, iii) expression phenotypes are primarily 
regulated by distant eQTLs17. 
Closing the gap between genotype and phenotype in complex diseases is proving complicated 
because, unlike Mendelian disorders, a large fraction of the associated loci are located outside 
known protein-coding regions.  Both empirical and computational data support the notion 
that a considerable proportion of these loci will be eQTLs18 19-21(and Pomerantz et al., PLoS 
Genetics In Press). The strategy of applying the genetics of gene expression approach offers 
an appealing and straightforward way to initiate the complicated task of connecting risk 
variants to their target genes.  Importantly, this strategy does not require knowledge of the 
actual causal allele.  
Many of the initial successful eQTL studies relied on lymphoblastoid cell lines largely due to 
their availability22,19. More recently, eQTL studies have been performed in primary human 
tissues and demonstrate that some of the associations are tissue-specific 20, 23 and Pomerantz 
et al ( PLoS Genetics, In Press).  A complementary and powerful approach to defining local 
eQTLs is to measure allelic imbalance in individuals that are heterozygous for a risk allele.  
Any transcript demonstrating a deviation from a 1:1 ratio (as typically measured by a 
transcribed heterozygous marker) becomes a strong candidate gene. 24-26 
What if the risk allele is not associated with the expression trait?  False negatives can occur 
because gene expression varies in time and space; therefore, the developmental time point 


































thumb, associations between the risk allele and expression should initially be tested in the cell 
lineage that is believe to give rise to the tumor type (and subtype) under study and contrasted 
with the expression patterns and associations in other tissues. Effects on transcript abundance 
may be subtle and therefore below the sensitivity threshold of a particular platform and/or 
sample size may not be adequate.  Transcript abundance is usually evaluated under steady-
state conditions.  Lastly, effects may only be revealed in certain contexts, such as the 
activation of a particular pathway.  In these cases, alternative assays will be required to 
implicate these genes. 
Future questions for the field include: What are the appropriate target tissues to examine?  
Risk alleles may act in a non-cell or -tissue autonomous fashion and therefore may exert their 
effect through other cell types that act upon the target tissue under consideration.  Should the 
diseased tissue or normal tissue or both be evaluated? We will address some of these points 
later in the article. Recent elegant research demonstrates that network analysis using risk 
variant and gene expression data is proving to be a powerful and fruitful tool in dissecting the 
pathways driving disease pathogenesis.  This ranges from transcriptomic analysis to predict 
the regulatory influence of transcription factors over gene networks dependency using tools 
such as ARACNE (Algorithm for the Reconstruction of Accurate Cellular Networks)27, 
through to Bayesian network approaches to identify predictive relationships between genes 
from a combination of expression and eQTL data28. Whilst these tools are elegant the ability 
to translate their outputs into biological significance is heavily dependent on the availability 
of manipulable and relevant model systems with which to test the predicted connectivity.  
These approaches clearly pose validation challenges for many diseases.  Finally, RNA-
sequencing (RNA-seq) using next generation sequencing platforms has the potential to reveal 
the transcriptome in its entirety.  The RNA-seq platform also possesses desirable 
characteristics such as increased sensitivity for low abundance transcripts and a wider 
dynamic range than microarrays.   
Epigenetics represents an additional tier of regulatory control relevant to 
understanding the transcriptional effects of SNPs in gene-distal or –proximal regions.  
Promoter methylation, histone tail modifications and altered expression of non-coding 
RNAs, such as the large intergenic noncoding RNAs  (lincRNAs)29,30 which associate with 
chromatin modifying complexes, contribute to gene regulation in normal development as well 
as to aberrant gene expression in tumorigenesis 31. Furthermore, epigenetic mechanisms play 
an important role in mediating environmental influences on gene expression 32. Epigenetic 
silencing has been shown to be the predominant mechanism of gene silencing for a subset of 
genes 33, while for other genes genetic as well as epigenetic mechanisms have been shown to 
jointly contribute to tumor suppressor gene activation 34. An important research direction in 
the field is to understand the interplay between environmental, genetic and epigenetic factors, 
both in healthy tissues as well as in the initiation and progression of malignancies. Here the 
focus is on two questions: (1) Do genetic variants alter the epigenetic landscape and in this 
way increase the susceptibility to develop cancer? (2) Do genetic variants increase the risk of 
a locus to become epigenetically silenced in the tumor? Technologies, in particular for the 
assessment of DNA methylation are now advanced and affordable enough to screen large 
tissue collections at a single CpG resolution 35. Methylation profiling in and around haplotype 
blocks associated with cancer risk thus represents one appropriate strategy. Mechanisms by 
which genetic variants have the ability to affect epigenetic marks are known from studies in 
hereditary non-polyposis colorectal cancer. Here constitutional epimutations exist, that 
predispose to early onset colorectal cancer 36,37. The MSH2 and MLH1 constitutional 


































of highly penetrant epigenetic predisposing factors. For example, mutation of TACSTD1 
leads to transcriptional inactivation through promoter methylation of a single MSH2 allele in 
normal somatic tissues. It has been proposed that many epimutations are a consequence of cis 
or trans acting genetic variants (reviewed in 38). In an elegant experiment Kerkel et al 39 
showed sequence dependence of allele-specific methylation and demonstrated that cis-
regulatory polymorphisms control gene expression and affect chromatin states. Recent Chip-
Seq data provides further compelling evidence that SNPs and structural variants frequently 
coincide with allele specific differences in transcription factor binding and chromatin 
structure. This can now be investigated using allele-specific sequence analysis approaches 40, 
although the depth of sequencing required for this approach is still an issue 41. Genome-wide 
maps of allelic asymmetries are expected to identify functional regulatory polymorphisms 42. 
The fact that SNPs can affect allelic imbalance in a tissue specific manner, as has been shown 
for UGT2B15 43, is important in the experimental design. Further epigenetic mechanisms 
modulating gene expression include miRNAs and miRNA binding sites which can directly be 
affected by SNPs 44, and tandem repeats that can impact gene expression e.g. by altering 
transcription factor binding sites, but also by affecting chromatin structure (reviewed in 45).  
Having used the approaches described above to generate a focused list of polymorphisms for 
functional follow-up, the subsequent challenge is to examine their impact in appropriate in 
vivo model systems.  The principal criterion for taking a polymorphism forward is the 
association of the eQTL with disease. 
Models for testing function 
Gaining a better understanding of the biological mechanisms of cancer development often 
relies on the analysis of models that reflect the human disease and the application of 
technologies that facilitate the analysis of these models (Table 1). It is likely that establishing 
a functional rationale underlying the significance of allelic variation and candidate genes at 
common low penetrance susceptibility loci in biologically relevant disease models will 
become a major component of following-up the data emerging from GWAS. Disease models 
can be based on either the in vitro characterization of human tissues (primary tissues or cells 
in culture) or in vivo models of disease development. Models are however generally limited 
to studying one variant/gene at a time.  It remains technically even more challenging to study 
cofounder effects, the possibility that multiple genes in a locus cooperate.  This mirrors 
challenges of assessing individual risk based on a statistical model in which SNPs interact, 
and indeed the statistical significance of associations between SNPs and disease is predicated 
on the idea of independent contributions from each SNP rather than a complex interplay. 
The basic hypothesis underpinning these studies is that genetic variation at susceptibility loci 
influences the initiation of the disease phenotype. Although the expression of several highly 
penetrant disease genes (e.g. BRCA1, BRCA2, APC) is ubiquitous, the functional effects of 
genetic variation are reflected in a tissue-specific manner. Therefore, it will be necessary to 
evaluate the functional effects of disease-associated SNPs in the precursor tissue.  
Another issue is the size of the functional effects expected for common genetic variants. 
Whereas the functional effects of several sequence alterations in genes such as BRCA1 and 
APC are clearly detrimental (they are usually coding sequence changes leading to defective 
protein products or abrogated expression), the functional effects of SNPs are likely to be 
subtle, and therefore likely to require large sample sizes in order to achieve sufficient power 
to detect associations. Thus, large bio-banks of normal tissues may need to be established to 
evaluate functional differences between the different alleles of a SNP. Establishing such 


































cancer research community have established tumor tissue bio-repositories, it has been less 
common to do so for normal tissues from the cells of origin of cancers. This issue is 
particularly problematic for tumor subtypes in which the cell of origin is still debated. 
Studies of normal tissues will need to be complemented by in vitro analyses using cell culture 
models. The location of SNPs with respect to candidate genes will provide multiple testable 
hypotheses about the functional consequence of genetic variants- for example whether or not 
SNPs lie in coding sequences, intronic regions, in well-defined gene promoters or stretches of 
chromatin enhancer sequences that may suggest a role in transcriptional regulation. Progress 
in establishing good models of normal tissues has been hampered by difficulties in accessing 
specimens, and the challenges of culturing primary cells. For example prostate epithelial cells 
are dependent on the presence of a co-cultured stromal component for establishing the 
secretory cell phenotype and functional differentiation. For the normal colon, most 
commercially available normal epithelial cell lines are fetal in origin, and differences in fetal 
and adult cell biology limits the translational potential of work using fetal cells to model adult 
epithelial cancer genesis. There are exceptions - in breast, well-characterized commercially 
available cell lines exist that represent good models of normal breast tissue, e.g. MCF10A 
cells and immortalized HMECs. Three-dimensional (3D) cultures of MCF10As form 
polarized cystic structures that closely reflect the architecture and molecular features of breast 
acini in vivo. By using such 3D models it is possible to dissect subtle phenotypes, such as 
changes associated with gene dosage. 
The development of in vitro models of human tumors, which represent the quickest and most 
accessible way to test the function of candidate genes located at susceptibility loci, are more 
advanced, but functional effects may be masked by an aberrant genetic background.  
Importantly most SNPs are reported to confer a predisposition to a particular disease and 
consequently we must expect that the greatest functional impact will be achieved in an 
essential healthy, non-aberrant tissue/background.  Such a context in which to study function 
is perhaps the hardest context to replicate and maintain in a laboratory situation meaning that 
there will be a continuous drive for improvements in the models used. 
Evaluating the functional effects of SNPs using in vivo models represents an even greater 
challenge. Even with genetically engineered animal models, several significant limitations in 
the biological validation of candidate genes remain including: 
 
o Relatively short duration of experimental models compared to human 
tumorigenesis that typically develops over several decades. 
o Important differences in human vs. animal physiology 
o Important differences in the structure and sequence of non-coding regions 
o Limited modelling of gene-environment interactions 
o Sensitivity of animal modelling to confirm function of low penetrance alleles 
when studied in isolation. 
Despite these limitations, animal models remain a vital tool for post-GWAS validation, 
particularly when considering quantitative phenotypes.  The multi-tumour APC-mutant mice 



































Exploring the functions of SNPs in regulatory sequences/regions: drawing the themes 
together. 
Functional SNPs found within large, non-coding intergenic intervals highlight the challenges 
of defining LD structure and pursuing functional validation.  One of the hypotheses to 
explain this is that the risk locus contains regulatory region(s) with element(s) affecting the 
expression of one or more distantly transcribed region(s) of the genome. Here the starting 
point is to explore whether they are components of regulatory elements and what their distal 
effects may be. Although the most abundant of these regulatory sequences are enhancers, 
they may also include other regulators such as insulators and silencers. Unlike promoters (at 
transcription start sites of genes), distal regulatory sequences, such as enhancers, are often 
cell-type specific 46 and thus may be targets for tissue-specific risk-SNP effects. Annotating 
such regulatory sequences using chromatin marks or DNase sensitivity has proven to be a 
powerful method47,48, and is more informative than the alternative approach of using 
evolutionary conservation, since regulatory elements tend to be unconstrained across 
mammalian evolution 49-51. Specifically, identifying regulatory sequences containing 
functional SNPs within response elements by using chromatin annotations has been proposed 
recently52. Additionally, demarcation of such regulatory regions is even more precisely 
achieved by assessing the association of candidate transcription factors with response 
elements. Both histone modifications and transcription factor occupied regions are currently 
identified using ChIP-seq methodologies and signals yield short DNA stretches (~1kb) 
amenable to detailed analyses. Enhancer activity in such regulatory regions can be assayed 
using reporter genes in vitro5 and/or in vivo47. Additionally, resequencing the target 
regulatory regions should then be prioritized to capture all the variation within them. Once 
activity is demonstrated, identified SNPs within the regions, especially ones within known 
transcription factor response elements and in LD with a tag-SNP, may be analyzed using 
biochemical methods for differential transcription factor binding and activity. Resequencing, 
targeting the regulatory regions, then should be prioritized to capture all the variation within 
them. Finally, regulatory sequences containing functional SNPs determined in this way can 
be matched with their physiological target genes to probe functional significance (see below). 
It is possible that multiple SNPs may function co-ordinately at a particular locus and each 
should be taken forward in subsequent mechanistic analyses. 
Three approaches are conceptually available to identify targets of regulatory sequences: (i) 
Target genes may be identified in regulatory sequences knockout mouse models (using cre-
lox for tissue-specific and timing purposes) by genome-wide gene expression analyses after 
the knockout; and (ii) Target genes may also be identified by using the regulatory sequences 
as baits in chromatin conformation capture (3C) based studies53,54, including genome-wide 
3C-seq; and (iii) Targeted editing using somatic cell knock-in technology, although 
technically demanding, is another approach. Allelic series in isogenic settings may be created 
and gene expression differences measured - either in naturally growing cells or in cells that 
are perturbed in some manner (e.g., radiation, hormones, etc.). Finally, these screening 
approaches should be followed by matching results from them, creating a list of robust targets 
that can each specifically be studied further. 
 Finally, these screening approaches should allow the matching of results from and between 
them, creating a priority list of robust potential targets that might each specifically be studied 
further. Thus, target genes under control of functional SNP-containing regulatory regions 
may have important roles in the cancer phenotype, such as proliferation, migration and 
apoptosis. Endpoints of the cancer phenotype, such as cell division, migration and apoptosis 


































after the overexpression of the genes of interest, or their selected siRNA/shRNA knockdown. 
It will also be important to develop ways to make this fine functional annotation data 
generated in these analyses freely accessible, because in many cases while they may not 
constitute publishable data they could be useful for other post-GWAS efforts.  
In summary the order of investigation is: identify chromatin architecture in tag-SNPS 
(+LD blocks)  assay for regulatory activity, such as enhancers  determine how SNPs in 
LD with the tag-SNP effect such activity  identify regulated target genes  understand 
biology/cancer risk  understand causal predisposition. 
Conclusion 
The GWAS community has arrived at an important crossroads.  As resources are limited the 
debate revolves around whether enough progress has been made towards identifying the 
SNPs that are likely to contribute most to disease causation to invest in functional follow-up.  
As sequencing technologies become cheaper and more accessible, we argue that this will 
evolve rapidly as datasets expand and will afford greater certainty in defining both SNPs and 
LD structure within the region in which they lie.  This will require a detailed mapping and 
annotation of epigenetic and transcriptomic landscapes within which a major limiter may 
prove to be the sample collections themselves.  Whilst this progresses, and hopefully does so 
increasingly through consortia assembled from academia and industry, it is vital that proof-
of-principle studies take forward the strongest candidate SNPs available so far, not in this 
case necessarily to test their causative association with disease but to understand their 
functional impact.  What makes for strong candidates are significant associations with 
transcript expression (eQTL analysis and chromosome conformation capture), tissue 
specificity and the phenotypic impacts of these transcript associations on model systems in 
downstream experiments.  Successfully making the experimental transitions to progress 
through this process will require collective working at a consortia/multi-group level and a 
clear decision tree.  It is essential for the field that this overrides the temptation to publish 
fragmentary work capturing only sub-steps in this sequence.  Over time integration of the re-
sequenced, epigenetic and molecular-epidemiological data within different ethnic groups (and 
thus within different linkage disequilibrium structures) will help localizing causal variants. If 
we begin considering how to explore the functional impact of SNPs now we will, as a 
community, be in good shape to rise to the challenge of testing causation in the future.  
The field is still making the first forays into the functional characterization of SNPs and is 
many steps away from proving causality.  Nonetheless our view is that causality can only be 
inferred if the eQTL is associated with disease and a SNP leads to expression differences in 
reliable in vitro and perhaps in vivo assays.  Naturally our ability to get close to this goal will 
need to be assessed in the context of current technologies and knowledge on a disease-by-
disease basis but we hope that this article will help to frame the developing debate and the 
emerging research that seeks to rise this great challenge. 
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Glossary 
3C, 4C, 5C, Hi-C, 3C-seq: chromosome conformation capture (3C) is a technique is used to 
identify interactions between genes and long-range regulatory made possible by chromosome 
loops that bring the two regions to physical proximity. Developments on this method include 
circularization (4C) of the genomic fragments with the use of inverse PCR primers, carbon 
copy (5C) technology for multiplexed ligation-mediated amplification, and high throughput 
analysis by massively parallel sequencing between many baits and targets (Hi-C), or many 
targets from a single locus (3C-seq). 
Supporting references: 55-5855-58 
 
Causal variant: In the context of GWAS it represents the SNP that is mechanistically linked 
to risk enhancement. This is distinct from SNPs that do not have any functional impact but 
are statistically associated with the disease phenotype because it is in linkage disequilibrium 
with the causal variant. 
Supporting evidence: 59  
 
ChIP-Seq: Chromatin immunoprecipitation (ChIP) is a method to study protein-DNA 
interactions. It identifies genomic regions that are binding sites for a known protein. Analysis 
of these regions is typically performed by PCR, when there is a hypothesized known binding 
site, or through the use of genomic microarrays (ChIP-chip). Alternatively, analysis can be 
done using next-generation sequencing (Seq) technology to analyze DNA fragments. 
Supporting references: 60,61  
 
CNV: Copy number variation is a type of structural variation in which a particular segment 
of the genome, typically larger than 1kb, is found to have a variable copy number from a 
reference genome. 
Supporting references: 62-64  
 
Deep sequencing: a sequencing strategy used to reveal variations present at extremely low 
levels in a sample. For example, to identify rare somatic mutations found in a small number 
of cells in a tumor, or low abundance transcripts in transcriptome analysis. 



































DNA Methylation: A modification of the DNA that involves predominantly the addition of a 
methyl group to the 5 position of the pyrimidine ring of a cytosine found in a CpG 
dinucleotide sequence. 
Supporting references: 66  
 
Epigenetic markers: an array of modifications to DNA and histones independent of changes 
in nucleotide sequence but rather the addition of methyl a methyl group to cytosine and a 
series of post-translation modifications of histone including methylation, acetylation, and 
phosphorylation. 
Supporting references: 67 
 
Fine mapping: a strategy to identify other lower frequency variants in a disease-associated 
region (typically spanning a haplotype block) not represented in the initial genotyping 
platform with the goal of uncovering candidate causal variants. It can include data mining of 
publically available sequencing efforts, such as the 1000 Genomes Project and targeted re-
sequencing.  
Supporting references: 59,68  
 
Functional variant: a variant that confers a detectable functional impact on the locus. It can 
represent a change in coding region but also changes in regulatory regions that have an 
impact on function.  
Supporting references:  55 
 
GWAS: genome-wide association study is a case-control study design in which most loci in 
the genome are interrogated for association with a trait (disease) through the use of SNPs by 
comparing allele frequencies in cases and controls. 
Supporting references: 1 
 
Haplotype block: linear segments of the genome comprising coinherited alleles in the same 
chromosome. 
Supporting references: 69,70 
 
Homologous recombination: an error-free recombination mechanism that exchanges genetic 
sequences between homologous loci during meiosis, and utilizes homologous sequences such 
as the sister-chromatid to promote DNA repair during mitosis. 



































Linkage disequilibrium: a nonrandom association between two markers (e.g. SNPs), which 
are typically close to one another due to reduced recombination between them. Supporting 
references: 69,71-73. 
 
MicroRNAs: endogenous short (~23 nt) RNAs involved in gene regulation by pairing to 
mRNAs of protein coding mRNAs. 
Supporting references: 74 
 
Next gen sequencing: a technology to sequence DNA in a massively parallel fashion, 
therefore sequencing is achieved at a much faster speed and lower cost than traditional 
methods.  
Supporting references: 67 
 
Non-coding variant: a variant that is located outside of the coding region of a certain locus. 
 
Tagging variant: a variant (SNP) that defines most of the haplotype diversity of a haplotype 
block. 
Supporting references: 69 
 
Transcriptome: The complete set of transcripts in a cell. In some cases it can also include 
quantitative data about the amount of individual transcripts. 
Supporting references: 65 
 
RNA-Seq: a method to obtain genome-wide transcription map using deep sequencing 
technologies to generate short sequence reads (30-400 bp). It reveals a transcriptional profile 
and levels of expression for each gene. 
Supporting references: 65 
 
SNP: single nucleotide polymorphism 
  
 



























































cell’s genotype by 
introduction/change
s in specific SNPs 
into cell lines (e.g. 
colorectal cancer 





Cell lines can be used 
for biochemistry 
studies, drug response 
screens, short and long 
term cell biological 
assays (e.g. apoptosis, 
survival fraction 
assays, soft agar 
growth assays).  
 
Limitations include the 
inability to assess 










screening of a large 
number of clones. 
Efficiency of 
integration may be 
gene specific as it 
depends on the 
structure of the 
homology segments 
flanking the target 
locus. While a 
targeting vector 
with a G418r (or 
Hygr) cassette 
driven by the 
phosphoglycerate 
kinase promoter can 
be effectively used 
to target regulatory 
regions, it is 
expected to increase 







  Mouse models: 
Generation of 




expression of target 






Allows study of effects 
of associated SNPs or 
associated genes in 
development and in the 
context of the whole 
organisms. 
Ability to assess 
effects of the 
microenvironment and 
paracrine effects.  
Mouse physiology not 
always similar to 
human. In particular 
Recombineering 
techniques for the 
production of BAC 











































 some tumor types and 
precursor lesions may 
be different in humans. 
tissue-specific 












































cell’s genotype by 
introduction/change
s in specific SNPs 





Same as described for 
cell lines (see above) 
The creation of a 





of off-the-shelf cell 












  Rat models: Rapid 
and targeted gene 
knockouts in ES 




several listed for 
mouse models. In 
addition, the anatomy 
and physiology of 
certain organs (e.g. 
prostate) is closer to 
humans than the 
mouse.  
Expensive to make 
and to maintain. 
References and 
resources: 86 

















































expression levels of 
associated genes to 




delivery generates high 
transduction 
efficiencies and can be 
done transiently or 
stably. Results may 
depend on the 
effectiveness of 
shRNA.  While there 
are clear advantages of 
using stable cell lines 
they may adapt to the 
knock down by 
acquiring additional 
mutations or the stable 
knock down might be 
incompatible with 
viability. Thus, both 




available sources of 
validated shRNAs, 
developed by the 
RNAi Consortium, 
cloned in lentiviral 
vectors that can be 




should be applied to 





























can also be used to 
modulate gene 
expression.   
Fast, easy, economical 
and reproducible. 
However, it is often 
difficult to obtain 
expression comparable 
to physiologic levels or 
in a cell cycle-specific 




Analysis should be 
performed in pools 
as well as in 
multiple clonal 
isolates to control 
for clonal variation 
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